Inhibikase Therapeutics
IKT
25 hedge funds and large institutions have $6.85M invested in Inhibikase Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
19% more funds holding
Funds holding: 21 → 25 (+4)
0.37% more ownership
Funds ownership: 2.72% → 3.09% (+0.37%)
12% less capital invested
Capital invested by funds: $7.78M → $6.85M (-$934K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$370K |
| 2 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
+$122K |
| 3 |
State Street
Boston,
Massachusetts
|
+$105K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$98.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$192K |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$184K |
| 3 |
Goldman Sachs
New York
|
-$53K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$24.9K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Envestnet Asset Management
Chicago,
Illinois
| – | -$21K | -1,831 | Closed |
|
27
Rockefeller Capital Management
New York
| – | -$2K | -250 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | +$55 | +5 | New |
|
IKT Hedge Fund Activity: Q4 2021 in Review
25 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2021, worth a combined $6.85M — down 12% from $7.78M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IKT positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $370K. The largest seller was Millennium Management, exiting entirely with an estimated $192K sold.
- 25 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2021, up from 21 in Q3 2021.
- Funds reported $6.85M of Inhibikase Therapeutics stock for Q4 2021, down 12% quarter-over-quarter.
- 8 funds opened new Inhibikase Therapeutics positions in Q4 2021 and 4 closed out, a net change of +4 holders.
- The largest Inhibikase Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $370K added.
- The largest Inhibikase Therapeutics seller in Q4 2021 was Millennium Management, an estimated $192K sold.
Based on aggregated 13F filings for Q4 2021.